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Identificationof risk factors for contracting anddeveloping serious illness following infection
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is of paramount
interest. Here, we performed a retrospective cohort analysis of all Danish individuals tested
for SARS-CoV-2 between 27 February 2020 and 30 July 2020, with a known ABO and RhD
blood group, to determine the influence of common blood groups on virus
susceptibility. Distribution of blood groups was compared with data from nontested
individuals. Participants (29% of whom were male) included 473 654 individuals tested
for SARS-CoV-2 using real-time polymerase chain reaction (7422 positive and 466 232
negative) and 2204742 nontested individuals, accounting for ;38% of the total Danish
population. Hospitalization and death from COVID-19, age, cardiovascular
comorbidities, and job status were also collected for confirmed infected cases. ABO
blood groups varied significantly between patients and the reference group, with only
38.41% (95% confidence interval [CI], 37.30-39.50) of the patients belonging to blood
group O compared with 41.70% (95% CI, 41.60-41.80) in the controls, corresponding to
a relative risk of 0.87 (95% CI, 0.83-0.91) for acquiring COVID-19. This study identifies
ABO blood group as a risk factor for SARS-CoV-2 infection but not for hospitalization or
death from COVID-19.
Introduction
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has spread rapidly since its emergence
in December 2019, causing a pandemic with 18093891 people infected globally (as of 3 August 2020).
In severe cases, individuals develop a number of symptoms, including acute respiratory illness, collectively
known as coronavirus disease 2019 (COVID-19). Development of COVID-19 is associated with age, sex,
and comorbidities, such as cardiovascular diseases,1 although severe disease is not limited to these risk
groups. Recent reports have suggested that ABO blood groups might play a role in the infection,2-6 with
a lower than expected prevalence of blood group O individuals among patients. ABO blood groups are
increasingly recognized to influence susceptibility to certain viruses, including SARS-CoV-17 and
norovirus.8,9 Blood group A and B glycosyltransferases also affect glycosylation in a large number of cell
types, including epithelial cells in the respiratory tract10 and shed viral particles.11,12 A, B, and AB
individuals are also at increased risk for thrombosis and cardiovascular diseases,13 which are important
comorbidities among hospitalized COVID-19 patients,14 possibly mediated by glycosylation of proteins
involved in hemostasis.15 To obtain valid estimates of relative risk (RR), representativeness of the reference
material is important. Although blood group frequencies and susceptibility for SARS-CoV-2 can vary
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substantially among ethnic groups, Denmark is a relatively ethnically
homogenous society with free access to health care services. Here,
we take of advantage of this, as well as the Danish centralized
registries, to compare the blood groups of 473654 individuals tested
for SARS-CoV-2 and stratified for severity, measured as hospitaliza-
tion or death from COVID-19.
Methods
Study design, variables, and oversight
A retrospective cohort analysis of all individuals with registered
ABO and RhD blood groups in Denmark was performed. Data
were extracted from electronic health records capturing all
Danish patients, the Danish Microbiology Database, the Danish
Civil Registration System, Danish Authorizations Register for
health care workers, the Danish Patient Safety Authorization
Register, and the Danish National Patient Register in a pseudo-
anonymized form.16 Information concerning ABO and RhD
blood groups, SARS-CoV-2 test results, and hospitalization
and/or death from COVID-19 was collected, as well as
demographic information (sex, age, authorization as health
care personnel) and cardiovascular comorbidities. Death from
COVID-19 was defined as death within 60 days following
diagnosis. Cardiovascular comorbidities were defined by the
10th revision of the International Statistical Classification of
Diseases and Related Health Problems codes for acute
myocardial infarction (I-21), heart failure (I-50), and cerebral
hemorrhage or infarction (I-60-64). Cases 60 years of age or
older were grouped as “older.”
According to Danish law, studies based entirely on registry data do
not require approval from an ethics review board.17 The study was
registered at the University of Southern Denmark’s data inventory
(record no. 10/960).
Study population
From 27 February 2020 to 30 July 2020, 841 327 individuals
were tested by real-time polymerase chain reaction for SARS-
CoV-2 infection in Denmark. Eligibility was determined by
whether ABO and RhD blood group information was avail-
able, which was the case for 473 654 individuals (56%). A
reference group with relevant blood group information from
2 204 742 nontested individuals was included (alive on 31
January 2020).
Supplemental Figure 1 outlines the testing strategy in Denmark
during the spring of 2020, which is explained in detail by Pottegård
et al.16 As a result of the strategy initially followed in Denmark,
a large number of health care workers are among the tested
individuals. Twenty-nine percent of this population was male, and
71% was female. The majority of patients (74%) in this study had
mild disease and were not hospitalized.
Study outcomes
The primary outcome was status of ABO and RhD blood groups
and test results for SARS-CoV-2. Secondary outcomes were
hospitalization and death from COVID-19.
Statistical methods
We report proportions for binary test results and occurrence of
clinical outcomes with accompanying 95% exact confidence
intervals (CIs). Equality of proportions between groups was tested
using a likelihood ratio x2 test and evaluated at a 5% significance
level. Because we had an a priori hypothesis about specific blood
groups affecting the risk of infection, we computed RRs for
contracting SARS-CoV-2 for each blood group. In a sensitivity
analysis, we modeled the potential impact that overrepresentation
of immigrants of nonwestern origin in the patient population could
have on the estimated risk ratios. All analyses were done in
Stata 16.
Results
Of 841327 people tested for SARS-CoV-2 in Denmark, ABO and
RhD blood groups could be identified for 473 654 individuals
(supplemental Figure 2). ABO and RhD data from 2204 742
individuals not tested for SARS-CoV-2 were used as a reference,
corresponding to ;38% of the entire Danish population.
Supplemental Figure 3 shows the demographic characteristics of
the tested population, stratified by sex and age. Of 473 654
individuals tested, 7422 were positive for SARS-CoV-2, and
466 232 were negative. In the population that tested negative for
SARS-CoV-2, 32.0% were men, and the median age was 50 years
(interquartile range, 36-64). Among positive cases, 32.9% were
men, and the median age was 52 years (interquartile range,
40-67).
The distribution of ABO groups among those tested and the
2 204742 nontested reference individuals is shown in Table 1.
There was a slight, but statistically significant, difference in blood
group distribution between the SARS-CoV-22 individuals and the
reference population (P , .001). Among the SARS-CoV-21
individuals, considerably fewer group O individuals were found
(P , .001); conversely, more A, B, and AB individuals were noted
(P , .001, P 5 .011, and P 5 .091, respectively). When blood
group O was excluded, no significant difference was seen
among A, B, and AB (P 5 .30). No difference in the RhD group
was found between positively tested cases and the reference
population (P 5 .15). We classified individuals after risk factors
associated with COVID-19, including age $60 years, cardio-
vascular comorbidity, and job in the health care sector. No
difference in the distribution of ABO groups was found when
infected individuals with a given risk factor were compared with
those without (all P . .1; supplemental Table 1). Together, these
data indicate that the RRs for contracting SARS-CoV-2 are 0.87
(95% CI, 0.83-0.91), 1.09 (95% CI, 1.04-1.14), 1.06 (95% CI,
0.99-1.14), and 1.15 (95% CI, 1.03-1.27) for O, A, B, and AB
individuals, respectively.
There was no difference (all P . .40) between ABO blood groups
and clinical severity of COVID-19 for nonhospitalized patients vs
hospitalized patients or for deceased patients vs living patients
(Table 2).
Immigrants from nonwestern countries and their first-generation
descendants are overrepresented among Danish COVID-19 patients
(constituting 18% of cases but only 9% of the population),18
which could confound the ABO distribution among SARS-CoV-
21 individuals. Therefore, we performed a sensitivity analysis by
calculating a weighted reference ABO distribution, taking into
account the number of COVID-19 cases among immigrants from
the nations constituting the largest sources of nonwestern
immigration in Denmark (Pakistan, Morocco, Somalia, Turkey,
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and Iraq) and reference ABO distributions in their respective
country of origin. Using this weighted ABO distribution as an
alternative reference population, we reanalyzed and found an
adjusted RR for blood group O individuals of 0.88 (supplemental
Table 2), which was very similar to our initial result (RR, 0.87;
Table 1).
Discussion
Here, we demonstrate that blood group O is significantly associated
with reduced susceptibility to SARS-CoV-2 infection. Additionally,
ABO blood groups were not associated with rates of hospitalization
or death following infection.
Our study has several limitations. ABO blood group information was
only available for 62% of all tested individuals, and only doctors and
nurses were identified as health care personnel. The sex of the
tested population was skewed, with females accounting for
71% of those who screened negative and 67% of those who
screened positive. However, blood groups are generally
independent of sex. More importantly, however, is the fact that
blood group distributions vary among ethnic subgroups with
different susceptibility for infection. Indeed, a higher than
expected contribution of immigrants from nonwestern countries
is noted among Danish COVID-19 patients,18 but a sensitivity
analysis indicated this is not a major bias and, thus, is unlikely to
affect the overall conclusion.
The data presented here are consistent with other studies
reporting primarily on hospitalized patients2-6 and those exploring
SARS-CoV-1 susceptibility.7 Several hypotheses could explain
these results. In vitro studies have indicated that SARS-CoV-1
particles can be glycosylated by the A variant of the ABO
glycosyltransferases, allowing anti-A antibodies to neutralize
the virus.11 Although not studied, it is likely to be the case for the
B variant, as well, and, therefore, for anti-B antibodies. Because
anti-A and anti-B are present on mucosal surfaces in some
individuals lacking the corresponding ABO blood group,19 this
might explain the relative protection of blood group O individuals.
In this context, it is interesting that the highest RR for infection
was found for blood group AB lacking both antibodies. However,
the RR of group AB did not differ significantly from that of group
A or B; because of the paucity of blood group AB, it would
require a considerably larger number of patients to clarify this.
Alternatively, the effect could be indirect, as a result of the association
between ABO blood groups and levels of von Willebrand factor,
which is higher in non-O individuals15 and who are also more prone to
arterial and venous thrombosis,20 which are important comorbidities
for COVID-19. Importantly, the majority of patients reported here
were not hospitalized and, therefore, were less likely to have such
comorbidities.
Our findings of similar relative protection by blood group O in
young individuals, in health care personnel, and in individuals
without a registered cardiovascular diagnosis suggest that
associations between non-O blood groups and comorbidities
do not explain the apparent protection enjoyed by group O
individuals, in line with findings reported by Zietz and Tatonetti.3
Moreover, our data do not indicate an association between
blood group and progression to hospitalization or death from
COVID-19. This is consistent with data from Ellinghaus et al,6
who did not find any differences in the usage of oxygen or
ventilation between ABO blood groups in hospitalized patients.
Given the known increased risk of thrombosis in non-O
individuals and the evolving central role for thrombosis in the
pathogenesis of COVID-19, it is important to explore this
aspect more closely in larger patient cohorts (eg, by examining
ABO blood type and viral load, the severity of symptoms, and
the long-term effects following COVID-19). Furthermore, it
should be emphasized that the 2 hypotheses do not exclude
each other.
Table 1. Distribution of ABO blood groups among individuals tested and not tested for SARS-CoV-2 in Denmark
Blood
group
SARS-CoV-2 tested, n (%)
Reference population,
n (%)
P, SARS-CoV-21 vs reference
population
RR (95% CI), positive individuals vs reference
populationPositive Negative
O 2851 (38.41) 193401 (41.48) 919303 (41.69) ,.001 0.87 (0.82-0.91)
A 3296 (44.41) 199211 (42.73) 934421 (42.39) ,.001 1.09 (1.02-1.13)
B 897 (12.09) 52 838 (11.33) 252559 (11.46) .091 1.06 (1.03-1.19)
AB 378 (5.09) 20 782 (4.46) 98 459 (4.47) .011 1.15 (1.05-1.31)
Total, n 7422 466232 2204742
Table 2. Distribution of ABO blood groups and clinical severity among individuals infected with SARS-CoV-2 in Denmark
Blood group
Confirmed SARS-CoV-2 infected, n (%)
P, hospitalized vs nonhospitalized P, deceased vs aliveHospitalized Nonhospitalized Deceased Alive
O 721 (36.96) 2130 (38.93) 201 (36.55) 2650 (38.56) .12 .35
A 896 (45.93) 2400 (43.87) 259 (47.09) 3037 (44.19) .12 .19
B 233 (11.94) 664 (12.14) 64 (11.64) 833 (12.12) .82 .74
AB 101 (5.18) 277 (5.06) 26 (4.73) 352 (5.12) .84 .68
Total, n 1951 5471 550 6872
7422 7422
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